Will treating progressive myopia overwhelm the eye care workforce? A workforce modelling study.


Journal

Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)
ISSN: 1475-1313
Titre abrégé: Ophthalmic Physiol Opt
Pays: England
ID NLM: 8208839

Informations de publication

Date de publication:
09 2022
Historique:
revised: 24 05 2022
received: 28 01 2022
accepted: 24 05 2022
pubmed: 22 6 2022
medline: 10 8 2022
entrez: 21 6 2022
Statut: ppublish

Résumé

Treatments for myopia progression are now available, but implementing these into clinical practice will place a burden on the eye care workforce. This study estimated the full-time equivalent (FTE) workforce required to implement myopia control treatments in the UK and Ireland. To estimate the number of 6- to 21-year-olds with myopia, two models utilising separate data sources were developed. The examination-based model used: (1) the number of primary care eye examinations conducted annually and (2) the proportion of these that are for myopic young people. The prevalence-based model used epidemiological data on the age-specific prevalence of myopia. The proportion of myopic young people progressing ≥0.25 dioptres (D)/year or ≥0.50 D/year was obtained from Irish electronic health records and the recommended review schedule from clinical management guidelines. Using the examination and prevalence models, respectively, the estimated number of young people with myopia was 2,469,943 and 2,235,713. The extra workforce required to provide comprehensive myopia management for this target population was estimated at 226-317 FTE at the 0.50 D/year threshold and 433-630 FTE at the 0.25 D/year threshold. Extra visits required for myopia control treatment represented approximately 2.6% of current primary eye care examinations versus 13.6% of hospital examinations. Implementing new myopia control treatments in primary care settings over the medium-term is unlikely to overwhelm the eye care workforce completely. Further increases to workforce, upskilling of current workforce and tools to reduce chair time will help to ensure sustainability of the eye care workforce into the future.

Identifiants

pubmed: 35726623
doi: 10.1111/opo.13019
pmc: PMC9543528
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1092-1102

Informations de copyright

© 2022 The Authors. Ophthalmic and Physiological Optics published by John Wiley & Sons Ltd on behalf of College of Optometrists.

Références

JAMA Ophthalmol. 2022 Feb 01;140(2):162-169
pubmed: 34989764
Ophthalmology. 2015 Jul;122(7):1489-97
pubmed: 25983215
Br J Ophthalmol. 2020 Mar;104(3):363-368
pubmed: 31142465
Ophthalmic Physiol Opt. 2019 Jul;39(4):225-231
pubmed: 31236977
Br J Ophthalmol. 2020 Jul;104(7):950-955
pubmed: 31653669
HRB Open Res. 2019 Nov 15;2:30
pubmed: 33083690
JAMA. 2020 Aug 11;324(6):571-580
pubmed: 32780139
Optom Vis Sci. 2019 Aug;96(8):556-567
pubmed: 31343513
PLoS One. 2016 Jan 19;11(1):e0146332
pubmed: 26783753
Ophthalmology. 2016 Feb;123(2):391-399
pubmed: 26271839
Ophthalmic Physiol Opt. 2011 Sep;31(5):550-8
pubmed: 21762431
Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):49
pubmed: 32347918
Curr Eye Res. 2016 May;41(5):600-8
pubmed: 26237276
Ophthalmology. 2019 Jan;126(1):113-124
pubmed: 30514630
Br J Ophthalmol. 2019 Aug;103(8):1112-1118
pubmed: 30315130
Ophthalmology. 2021 Nov;128(11):1561-1579
pubmed: 33961969
Br J Ophthalmol. 2016 Jul;100(7):882-890
pubmed: 26802174
Br J Ophthalmol. 2014 Jan;98(1):40-5
pubmed: 24169657
Ophthalmology. 2016 Apr;123(4):697-708
pubmed: 26826749
Ophthalmology. 2020 Jul;127(7):910-919
pubmed: 32019700
Br J Ophthalmol. 2022 Aug;106(8):1104-1109
pubmed: 33712479
PLoS One. 2015 Apr 09;10(4):e0124535
pubmed: 25855979
Clin Exp Ophthalmol. 2020 Jul;48(5):569-579
pubmed: 32100917
Ophthalmology. 2016 May;123(5):1036-42
pubmed: 26875007
HRB Open Res. 2019 Jul 23;2:15
pubmed: 32002514
JAMA Ophthalmol. 2016 Dec 01;134(12):1355-1363
pubmed: 27768171
Ophthalmic Physiol Opt. 2022 Sep;42(5):1092-1102
pubmed: 35726623
Invest Ophthalmol Vis Sci. 2019 Feb 28;60(3):M184-M203
pubmed: 30817832
Eye (Lond). 2009 May;23(5):1086-9
pubmed: 18670466
Optom Vis Sci. 2021 May 1;98(5):500-511
pubmed: 33973918
Invest Ophthalmol Vis Sci. 2008 Sep;49(9):3858-63
pubmed: 18469186
Lancet Glob Health. 2021 Feb;9(2):e144-e160
pubmed: 33275949
Bull World Health Organ. 2009 Jun;87(6):431-7
pubmed: 19565121
Eye (Lond). 2009 Mar;23 Suppl 1:S1-7
pubmed: 19287467
Br J Ophthalmol. 2010 Sep;94(9):1150-4
pubmed: 20558427

Auteurs

Gareth Lingham (G)

Centre for Eye Research Ireland, Environmental Sustainability and Health Institute, Technological University Dublin, Dublin, Ireland.

James Loughman (J)

Centre for Eye Research Ireland, Environmental Sustainability and Health Institute, Technological University Dublin, Dublin, Ireland.

Stella Kuzmenko (S)

Centre for Eye Research Ireland, Environmental Sustainability and Health Institute, Technological University Dublin, Dublin, Ireland.

Matilda Biba (M)

Centre for Eye Research Ireland, Environmental Sustainability and Health Institute, Technological University Dublin, Dublin, Ireland.

Daniel Ian Flitcroft (DI)

Centre for Eye Research Ireland, Environmental Sustainability and Health Institute, Technological University Dublin, Dublin, Ireland.
Department of Ophthalmology, Children's University Hospital, Dublin, Ireland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH